News

An international group of researchers, including Avivia CEO Hans Platteeuw, believe there is ample evidence that antimalarial drugs can be used to treat COVID-19 and that they should be assessed for their efficacy in clinical trials.

The research group, from institutions across Europe, Asia and Africa, point to a combination of the drugs artesunate and pyronaridine as the most promising.

The public-private consortium to run this project includes leading academic groups and for-profit parties with a track record in drug discovery and development, extensive knowledge of medicinal chemistry and virology. The development of an effective treatment and prophylactic agent for COVID-19 will have a profound social and economic impact today. In addition, a broad spectrum antiviral will help to contain/curb future epidemic coronavirus outbreaks and to treat future patients.